PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
42.50
+2.02 (4.99%)
Oct 29, 2024, 4:00 PM EDT - Market closed

Company Description

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally.

The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.

Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington’s disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis.

The company distributes its products through third-party distributors. It has collaborations with F.

Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

PTC Therapeutics, Inc.
PTC Therapeutics logo
Country United States
Founded 1998
IPO Date Jun 20, 2013
Industry Biotechnology
Sector Healthcare
Employees 1,055
CEO Matthew Klein

Contact Details

Address:
100 Corporate Court
South Plainfield, New Jersey 07080
United States
Phone 908 222 7000
Website ptcbio.com

Stock Details

Ticker Symbol PTCT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001070081
CUSIP Number 69366J200
ISIN Number US69366J2006
Employer ID 04-3416587
SIC Code 2834

Key Executives

Name Position
John Baird Ph.D. Chief of Staff to the Chief Executive Officer
Dr. Matthew B. Klein F.A.C.S., M.D., M.S. Chief Executive Officer and Director
Dr. Stuart W. Peltz Ph.D. Co-Founder, Senior Consultant and Member of Scientific Advisory Board
Dr. Allan Steven Jacobson Ph.D. Co-Founder, Chairman of Scientific Advisory Board and Independent Director
Pierre Gravier M.S. Chief Financial Officer
Mark Elliott Boulding Executive Vice President and Chief Legal Officer
Eric Pauwels Chief Business Officer
Dr. Lee Golden M.D., Ph.D. Executive Vice President and Chief Medical Officer
Christine Utter Senior Vice President, Chief Accounting Officer and Head of People Services
Dr. Neil Almstead Ph.D. Chief Technical Operations Officer

Latest SEC Filings

Date Type Title
Oct 18, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 18, 2024 8-K Current Report
Aug 8, 2024 10-Q Quarterly Report
Aug 8, 2024 8-K Current Report
Jul 16, 2024 144 Filing
Jun 28, 2024 8-K Current Report
Jun 20, 2024 8-K Current Report
May 22, 2024 144 Filing
May 20, 2024 8-K Current Report
May 7, 2024 144 Filing